Patents by Inventor Stefan Rose-John

Stefan Rose-John has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 9765129
    Abstract: The present invention relates generally to a method of increasing lipid oxidation in a mammal and to agents useful for same. More particularly, the present invention relates to a method of increasing lipid oxidation in a mammal by administering a ligand which interacts with the IL-6 receptor and signals via interaction with a gp130/LIF receptor heterodimer. In a related aspect, the present invention provides a method of increasing insulin sensitivity in a mammal. The method of present invention is useful, inter alia, in the treatment and/or prophylaxis of conditions characterized by unwanted lipid accumulation (such as obesity, obesity induced-metabolic disorders, type II diabetes, dyslipidemia, glucose intolerance, insulin resistance, obstructive sleep apnea, cardiovascular disease or non-alcoholic fatty liver disease) or inadequate insulin sensitivity.
    Type: Grant
    Filed: August 16, 2013
    Date of Patent: September 19, 2017
    Assignees: Baker Medical Research Institute, Christian-Albrechts-Universität zu Kiel
    Inventors: Mark Anthony Febbraio, Stefan Rose-John
  • Patent number: 9187542
    Abstract: Nucleic acid molecule selected from the group consisting of (a) a nucleic acid molecule having a nucleotide sequence shown in SEQ ID: NO 1, (b) a nucleic acid molecule which encodes a peptide having an amino acid sequence shown in SEQ ID: NO 2, (c) a nucleic acid molecule whose complementary strand hybridizes to a nucleic acid molecule according to (a) or (b) and which codes for a peptide which binds to ciliary neurotrophic factor receptor (CNTFR), the peptide binding with lower affinity than ciliary neurotrophic factor to the interleukin-6 receptor (IL-6R), (d) a nucleic acid molecule whose nucleotide sequence differs from the nucleotide sequence of a nucleic acid molecule according to (c) due to the degenerated genetic code, the codon at positions 82-84 of the nucleic acid molecule according to (a) coding for a non-positively charged amino acid, and the peptide at position 28 shown in SEQ ID: NO 2 having a non-positively charged amino acid residue.
    Type: Grant
    Filed: June 13, 2012
    Date of Patent: November 17, 2015
    Assignee: CHRISTIAN-ALBRECHTS-UNIVERSITAT ZU KIEL
    Inventors: Joachim Grötzinger, Stefan Rose-John, Jürgen Scheller, Matthias Aurich
  • Publication number: 20140171620
    Abstract: Nucleic acid molecule selected from the group consisting of (a) a nucleic acid molecule having a nucleotide sequence shown in SEQ ID: NO 1, (b) a nucleic acid molecule which encodes a peptide having an amino acid sequence shown in SEQ ID: NO 2, (c) a nucleic acid molecule whose complementary strand hybridizes to a nucleic acid molecule according to (a) or (b) and which codes for a peptide which binds to ciliary neurotrophic factor receptor (CNTFR), the peptide binding with lower affinity than ciliary neurotrophic factor to the interleukin-6 receptor (IL-6R), (d) a nucleic acid molecule whose nucleotide sequence differs from the nucleotide sequence of a nucleic acid molecule according to (c) due to the degenerated genetic code, the codon at positions 82-84 of the nucleic acid molecule according to (a) coding for a non-positively charged amino acid, and the peptide at position 28 shown in SEQ ID: NO 2 having a non-positively charged amino acid residue.
    Type: Application
    Filed: June 13, 2012
    Publication date: June 19, 2014
    Applicant: CHRISTIAN-ALBRECHTS-UNIVERSITAT ZU KIEL
    Inventors: Joachim Grötzinger, Stefan Rose-John, Jurgen Scheller, Matthias Aurich
  • Publication number: 20140140949
    Abstract: The present invention relates generally to a method of increasing lipid oxidation in a mammal and to agents useful for same. More particularly, the present invention relates to a method of increasing lipid oxidation in a mammal by administering a ligand which interacts with the IL-6 receptor and signals via interaction with a gp130/LIF receptor heterodimer. In a related aspect, the present invention provides a method of increasing insulin sensitivity in a mammal. The method of present invention is useful, inter alia, in the treatment and/or prophylaxis of conditions characterised by unwanted lipid accumulation (such as obesity, obesity induced-metabolic disorders, type II diabetes, dyslipidemia, glucose intolerance, insulin resistance, obstructive sleep apnea, cardiovascular disease or non-alcoholic fatty liver disease) or inadequate insulin sensitivity.
    Type: Application
    Filed: August 16, 2013
    Publication date: May 22, 2014
    Applicants: Christian-Albrechts-Universität Zu Kiel, Baker Medical Research Institute
    Inventors: Mark Anthony Febbraio, Stefan Rose-John
  • Publication number: 20140072984
    Abstract: Described are soluble gp130 polypeptide monomers and dimers, wherein, in a preferred embodiment, at least one of the three amino acid residues Thr102 GIn113 or ASn114 of the N-terminal Ig-like domain of gp130 is mutated to Tyr102, Phe113 or Leu114, respectively. These mutations, alone or in combination, specifically enhance binding of gp130 to its ligand complex of interleukin-6 and soluble interleukin-6 receptor, thus increasing the biological activity of the gp130 muteins. In a particularly preferred embodiment, all three mutations are combined in the triple mutein Thr102Tyr/Gln113Phe/Asn114Leu (T102Y/Q113F/N114L). Moreover, a pharmaceutical composition containing said monomers or dimers and various medical uses are described.
    Type: Application
    Filed: June 20, 2013
    Publication date: March 13, 2014
    Applicant: Conaris Research Institute AG
    Inventors: Joachim Grötzinger, Jürgen Scheller, Stephanie Tenhumberg, Stefan Rose-John, Georg H. Wätzig
  • Patent number: 8501696
    Abstract: Described are soluble gp130 polypeptide monomers and dimers, wherein, in a preferred embodiment, at least one of the three amino acid residues Thr102 Gln113 or Asn114 of the N-terminal Ig-like domain of gp130 is mutated to Tyr102, Phe113 or Leu114, respectively. These mutations, alone or in combination, specifically enhance binding of gp130 to its ligand complex of interleukin-6 and soluble interleukin-6 receptor, thus increasing the biological activity of the gp130 muteins. In a particularly preferred embodiment, all three mutations are combined in the triple mutein Thr102Tyr/Gln113Phe/Asn114Leu (T102Y/Q113F/N114L). Moreover, a pharmaceutical composition containing said monomers or dimers and various medical uses are described.
    Type: Grant
    Filed: October 15, 2008
    Date of Patent: August 6, 2013
    Assignee: Conaris Research Institute AG
    Inventors: Joachim Grötzinger, Jürgen Scheller, Stephanie Tenhumberg, Stefan Rose-John, Georg H. Wätzig
  • Patent number: 8372389
    Abstract: The present invention relates to methods for preventing or treating toxicities associated with exposure to ionizing radiation or to chemotherapy. Particularly, the present invention relates to methods for preventing or treating toxicities associated with radiation or chemotherapy comprising administering to a subject in need of such treatment polypeptide complexes comprising an IL-6 linked to a soluble IL-6 receptor, the polypeptide complexes capable of preventing or treating toxicities, particularly xerostomia.
    Type: Grant
    Filed: November 27, 2008
    Date of Patent: February 12, 2013
    Assignees: Hadasit Medical Research Services and Development Ltd., Christian-Albrechts-Universitat Zu Kiel
    Inventors: Jonathan H. Axelrod, Eithan Galun, Stefan Rose-John, Ytzhack Marmary
  • Patent number: 8206948
    Abstract: Described are codon optimized sgp130 encoding nucleic acid molecules as well as a method for the highly efficient recombinant production of sgp130 in mammalian cells or bacteria using a nucleic acid molecule of the invention.
    Type: Grant
    Filed: August 26, 2005
    Date of Patent: June 26, 2012
    Assignee: Conaris Research Institute AG
    Inventors: Dirk Seegert, Georg Wätzig, Nikolaus Rahaus, Jessica Daecke, Stefan Rose-John
  • Publication number: 20110184220
    Abstract: The present invention relates to methods for preventing or treating toxicities associated with exposure to ionizing radiation or to chemotherapy. Particularly, the present invention relates to methods for preventing or treating toxicities associated with radiation or chemotherapy comprising administering to a subject in need of such treatment polypeptide complexes comprising an IL-6 linked to a soluble IL-6 receptor, the polypeptide complexes capable of preventing or treating toxicities, particularly xerostomia.
    Type: Application
    Filed: November 27, 2008
    Publication date: July 28, 2011
    Inventors: Jonathan H. Axelrod, Eithan Galun, Stefan Rose-John, Ytzhack Marmary
  • Patent number: 7897145
    Abstract: The present invention relates to methods for treating renal failure. Particularly, the present invention relates to methods for treating renal failure by administering to a subject complexes that include a member of the IL-6 family linked to a soluble receptor of the member of the IL-6 family, or isolated polynucleotides encoding same, the complexes capable of activating a gp130 mediated signaling pathway, thereby treating acute or chronic renal failure.
    Type: Grant
    Filed: June 15, 2006
    Date of Patent: March 1, 2011
    Assignee: Hadasit Medical Research Services and Development Ltd.
    Inventors: Jonathan Axelrod, Daniel Barkan, Eithan Galun, Yael Nehemia, Stefan Rose-John
  • Publication number: 20100298236
    Abstract: Described are soluble gp130 polypeptide monomers and dimers, wherein, in a preferred embodiment, at least one of the three amino acid residues Thr102 Gln113 or Asn114 of the N-terminal Ig-like domain of gp130 is mutated to Tyr102, Phe113 or Leu114, respectively. These mutations, alone or in combination, specifically enhance binding of gp130 to its ligand complex of interleukin-6 and soluble interleukin-6 receptor, thus increasing the biological activity of the gp130 muteins. In a particularly preferred embodiment, all three mutations are combined in the triple mutein Thr102Tyr/Gln113Phe/Asn114Leu (T102Y/Q113F/N114L). Moreover, a pharmaceutical composition containing said monomers or dimers and various medical uses are described.
    Type: Application
    Filed: October 15, 2008
    Publication date: November 25, 2010
    Inventors: Joachim Grötzinger, Jürgen Scheller, Stephanie Tenhumberg, Stefan Rose-John, George H. Wätzig
  • Publication number: 20100209385
    Abstract: The present invention relates generally to a method of increasing lipid oxidation in a mammal and to agents useful for same. More particularly, the present invention relates to a method of increasing lipid oxidation in a mammal by administering a ligand which interacts with the IL-6 receptor and signals via interaction with a gp130/LIF receptor heterodimer. In a related aspect, the present invention provides a method of increasing insulin sensitivity in a mammal. The method of present invention is useful, inter alia, in the treatment and/or prophylaxis of conditions characterised by unwanted lipid accumulation (such as obesity, obesity induced-metabolic disorders, type II diabetes, dyslipidemia, glucose intolerance, insulin resistance, obstructive sleep apnea, cardiovascular disease or non-alcoholic fatty liver disease) or inadequate insulin sensitivity.
    Type: Application
    Filed: March 28, 2008
    Publication date: August 19, 2010
    Inventors: Mark Anthony Febbraio, Stefan Rose-John
  • Publication number: 20100135952
    Abstract: The present invention relates to methods for treating renal failure. Particularly, the present invention relates to methods for treating renal failure by administering to a subject complexes that include a member of the IL-6 family linked to a soluble receptor of the member of the IL-6 family, or isolated polynucleotides encoding same, the complexes capable of activating a gp130 mediated signaling pathway, thereby treating acute or chronic renal failure.
    Type: Application
    Filed: June 15, 2006
    Publication date: June 3, 2010
    Inventors: Jonathan Axelrod, Daniel Barkan, Eithan Galun, Yael Nehemia, Stefan Rose-John
  • Patent number: 7629147
    Abstract: A polypeptide-dimer comprising two soluble gp130 molecules is described, wherein at least one of said soluble gp130 molecules is covalently linked to polyethylene glycol. Furthermore, a pharmaceutical composition containing said dimer and various medical uses are described.
    Type: Grant
    Filed: February 5, 2008
    Date of Patent: December 8, 2009
    Assignee: Conaris Research Institute AG
    Inventors: Dirk Seegert, Stefan Schreiber, Stefan Rose-John, Georg H. Watzig, Nikolaus Rahaus
  • Patent number: 7534862
    Abstract: A polypeptide-dimer comprising two soluble gp130 molecules is described, wherein at least one of said soluble gp130 molecules is covalently linked to polyethylene glycol. Furthermore, a pharmaceutical composition containing said dimer and various medical uses are described.
    Type: Grant
    Filed: June 23, 2004
    Date of Patent: May 19, 2009
    Assignee: Conaris Research Institute AG
    Inventors: Dirk Seegert, Stefan Schreiber, Stefan Rose-John, Georg H. Watzig, Nikolaus Rahaus
  • Publication number: 20090010872
    Abstract: The present invention concerns a new designer cytokine termed H11, which is constructed by fusion of two soluble components, soluble interleukin 11 receptor (sIL-11 R) and interleukin 11 (IL-11) using their natural sequence and its use for the production of a medicament for treating or preventing a disease selected from the group consisting of a proliferative disease, a cytopathy, radiation damage, an IL-11 dependent inflammatory disorder, IL-11 dependent degenerative disorder and IL-11 dependent or mediated soft tissue disorder.
    Type: Application
    Filed: May 20, 2005
    Publication date: January 8, 2009
    Inventors: Andrzej Mackiewicz, Hanna Dams-Kozlowska, Stefan Rose-John
  • Publication number: 20080227155
    Abstract: A polypeptide-dimer comprising two soluble gp130 molecules is described, wherein at least one of said soluble gp130 molecules is covalently linked to polyethylene glycol. Furthermore, a pharmaceutical composition containing said dimer and various medical uses are described.
    Type: Application
    Filed: February 5, 2008
    Publication date: September 18, 2008
    Inventors: Dirk Seegert, Stefan Schreiber, Stefan Rose-John, Georg H. Watzig, Nikolaus Rahaus
  • Publication number: 20080199906
    Abstract: Described are codon optimized sgp130 encoding nucleic acid molecules as well as a method for the highly efficient recombinant production of sgp130 in mammalian cells or bacteria using a nucleic acid molecule of the invention.
    Type: Application
    Filed: August 26, 2005
    Publication date: August 21, 2008
    Applicant: CONARIS RESEARCH INSTITUTE AG
    Inventors: Dirk Seegert, Georg Watzig, Nikolaus Rahaus, Jessica Daecke, Stefan Rose-John
  • Publication number: 20070270334
    Abstract: A polypeptide-dimer comprising two soluble gp130 molecules is described, wherein at least one of said soluble gp130 molecules is covalently linked to polyethylene glycol. Furthermore, a pharmaceutical composition containing said dimer and various medical uses are described.
    Type: Application
    Filed: June 23, 2004
    Publication date: November 22, 2007
    Inventors: Dirk Seegert, Stefan Schreiber, Stefan Rose-John, Georg Watzig, Nikolaus Rahaus
  • Patent number: 7112436
    Abstract: The present invention concerns a conjugate comprising two polypeptides with a mutual affinity, the polypeptides being connected with each other via a linker. This invention also concerns the use of such a conjugate to influence interactions between proteins.
    Type: Grant
    Filed: March 7, 1997
    Date of Patent: September 26, 2006
    Assignee: Angewandte Gentechnologie Systeme GmbH
    Inventor: Stefan Rose-John